Electrophysiologic Measures of Treatment Response in Alzheimer Disease

This study has been completed.

First Received: July 3, 2001 Last Updated: January 20, 2009 History of Changes

Sponsored by:	Department of Veterans Affairs
Information provided by:	Department of Veterans Affairs
ClinicalTrials.gov Identifier:	NCT00018278

Purpose

The main purpose of this study is to determine the electrophysiological effects of cholinergic therapy (cholinesterase inhibitors and transdermal nicotine) in Alzheimer disease. The attempt will be to locate electrophysiological markers and predictors of cognitive and clinical treatment response.

Condition	Intervention	Phase
Alzheimer Disease	Drug: Aricept Drug: Exelon Drug: Nicoderm Patch	Phase IV

Study Type:	Interventional
Study Design:	Treatment, Non-Randomized, Open Label, Uncontrolled, Crossover Assignment, Efficacy Study
Official Title:	Verbal Memory ERPs as Indices of Treatment Response in Alzheimer Disease

Resource links provided by NLM:

Genetics Home Reference related topics: Alzheimer disease

MedlinePlus related topics: Alzheimer's Disease

U.S. FDA Resources

Further study details as provided by Department of Veterans Affairs:

Study Start Date:	October 1998
Estimated Study Completion Date:	September 2001

Eligibility

Ages Eligible for Study:	55 Years to 85 Years
Genders Eligible for Study:	Both
Accepts Healthy Volunteers:	Yes

Criteria

Patients diagnosed with mild to moderate probable Alzheimer's disease (mini-mental state exam scores between 15-27), and normal controls (age generally between 60-85). Subjects must either be planning to start daily cholinesterase therapy (e.g. Aricept, Exelon) or willing to try a transdermal nicotine patch for two 8 hour periods.

Contacts and Locations

Please refer to this study by its ClinicalTrials.gov identifier: NCT00018278

Locations

United States, California
Department of Veterans Affairs
San Diego, California, United States, 92161

Sponsors and Collaborators

Department of Veterans Affairs

Investigators

Investigator:	Vincente Iragui, M.D., Ph.D
Investigator:	Shuanna Morris, Ph.D.

More Information

No publications provided

Study ID Numbers:	AGCG-004-98S
Study First Received:	July 3, 2001
Last Updated:	January 20, 2009
ClinicalTrials.gov Identifier:	NCT00018278 History of Changes
Health Authority:	United States: Federal Government

Study placed in the following topic categories:

Nicotine polacrilex
Rivastigmine
Alzheimer Disease
Central Nervous System Diseases
Brain Diseases
Neurodegenerative Diseases
Cognition Disorders

Delirium, Dementia, Amnestic, Cognitive Disorders
Mental Disorders
Nicotine
Donepezil
Dementia
Delirium

Additional relevant MeSH terms:

Delirium, Dementia, Amnestic, Cognitive Disorders
Mental Disorders
Nervous System Diseases
Alzheimer Disease
Central Nervous System Diseases

Neurodegenerative Diseases
Tauopathies
Brain Diseases
Dementia

ClinicalTrials.gov processed this record on September 04, 2009